Polypharmacy in Older Adults Elderly: What Medication to Discontinue

Polypharmacy is certainly a problem in the elderly population. Forgetfulness, and drug and dose confusion can lead to multiple problems; in addition, over time, cognitive deterioration will make complicated drug management schemes even more difficult for patients to handle. 

Polifarmacia en adultos mayores ¿Qué medicación no podemos suspender?

Aware of this problem, physicians often try to simplify schemes by discontinuing drugs, but what should we discontinue when it means risking patient health? This study recently presented at JAMA at least clarifies what drug NEVER to discontinue. 

The study looked at a cohort of 29,047 patients older than 65 who were on statins, hypertensive medication, antidiabetics and antiplatelets between 2013 and 2015.

This study was particularly focused on patients discontinuing statins. These were matched using propensity score to be compared against patients who stayed on all medication (statins and the rest). 

Of the total population of nearly 30,000 patients, 20% discontinued statins and kept taking the rest of prescribed medication; the rest of the population kept taking all drugs and served as control group. 

Patients discontinuing statins had higher risk of hospitalization for cardiac failure (HR 1.24; CI 95%, 1.07-1.43), any adverse cardiovascular event (HR, 1.14; CI 95%, 1.03-1.26), all cause death (HR, 1.15; CI 95%, 1.02-1.30) and emergency hospitalization for any cause (HR, 1.12; CI 95%, 1.05-1.19). 


Read also: Myocarditis and mRNA COVID-19 Vaccines: New Information from the CDC.


Comorbidities rate resulted very similar in both groups, which makes it hard to believe doctors would discontinue statins because of patient frailty. 

Conclusion

Patients receiving polypharmacy who for whatever reason discontinue statins (while still taking the rest of prescribed drugs) present increased risk of fatal and non-fatal events. 

rea-2021-oi-210393-1622769937-85783

Original Title: Cardiovascular Outcomes and Mortality Associated With Discontinuing Statins in Older Patients Receiving Polypharmacy.

Reference: Federico Rea et al. JAMA Netw Open. 2021 Jun 1;4(6):e2113186. doi: 10.1001/jamanetworkopen.2021.13186.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Is it safe to use negative chronotropic drugs early after TAVI?

TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Dual Antiplatelet Therapy in Diabetic Patients with AMI: De-Escalation Strategy

Diabetes Mellitus (DM) is a common comorbidity in patients hospitalized for acute coronary syndrome (ACS) of increasing prevalence over the last decade, associated with...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

Endoleaks after endovascular repair of complex aortic aneurysms: always reintervene or monitor with CTA?

Endovascular repair of thoracoabdominal aneurysms requiring sealing above the renal arteries, with preservation of visceral vessels using fenestrated and/or branched devices (F/B-EVAR), has become...

Is it safe to use negative chronotropic drugs early after TAVI?

TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...